MedTrace Logo

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

NCT05061251 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2022-01-11

No results posted yet for this study

Summary

This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.

Conditions

Interventions

DRUG

BAY 2402234

Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Kalil g Abdullah, MD, MSc · UT Southwestern/ Simmons CC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-01
Completion
2023-12-01
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05061251 on ClinicalTrials.gov